Global Circulating Tumor DNA Diagnostics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 87

Published Date: 12 Aug 2022

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Circulating Tumor DNA Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 and Russia-Ukraine War influence, the global Circulating Tumor DNA Diagnostics market size was valued at USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period.

The Circulating Tumor DNA Diagnostics market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the global market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.

Hospitals occupied for % of the Circulating Tumor DNA Diagnostics global market in 2021, and it is projected to value USD million by 2028, growing at a % CAGR in next six years. In terms of product type, Test Kits segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Circulating Tumor DNA Diagnostics include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics and Freenome Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.

Key Features of This Report:
This report provides in-depth analysis of the global Circulating Tumor DNA Diagnostics market, and provides market size and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year.

Main Circulating Tumor DNA Diagnostics companies’ industry ranking, revenue, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This reports profiles key players in the global Circulating Tumor DNA Diagnostics market based on the following parameters – headquarters, products portfolio, Circulating Tumor DNA Diagnostics revenue, and gross margin, recent developments.

Evaluation and forecast the Circulating Tumor DNA Diagnostics market size, projected growth trends, and corresponding market share analysis by type, by application, and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market segmentation
Circulating Tumor DNA Diagnostics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of revenue. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type (2017-2028; USD Million)
Test Kits
Reagents

Market segment by Application (2017-2028; USD Million)
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes

The key market players for global Circulating Tumor DNA Diagnostics market are listed below:
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life

Region Segment (2017-2028; USD Million)
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Circulating Tumor DNA Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Circulating Tumor DNA Diagnostics, with revenue, gross margin and global market share of Circulating Tumor DNA Diagnostics from 2019 to 2022.
Chapter 3, the Circulating Tumor DNA Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Circulating Tumor DNA Diagnostics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Circulating Tumor DNA Diagnostics research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Circulating Tumor DNA Diagnostics
    1.2 Classification of Circulating Tumor DNA Diagnostics by Type
        1.2.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type in 2021
        1.2.3 Test Kits
        1.2.4 Reagents
    1.3 Global Circulating Tumor DNA Diagnostics Market by Application
        1.3.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Hospitals
        1.3.3 Diagnostics Laboratories
        1.3.4 Research Laboratories
        1.3.5 Academic Research Institutes
    1.4 Global Circulating Tumor DNA Diagnostics Market Size & Forecast
    1.5 Global Circulating Tumor DNA Diagnostics Market Size and Forecast by Region
        1.5.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Circulating Tumor DNA Diagnostics Market Size by Region, (2017-2022)
        1.5.3 North America Circulating Tumor DNA Diagnostics Market Size and Prospect (2017-2028)
        1.5.4 Europe Circulating Tumor DNA Diagnostics Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size and Prospect (2017-2028)
        1.5.6 South America Circulating Tumor DNA Diagnostics Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Circulating Tumor DNA Diagnostics Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Circulating Tumor DNA Diagnostics Market Drivers
        1.6.2 Circulating Tumor DNA Diagnostics Market Restraints
        1.6.3 Circulating Tumor DNA Diagnostics Trends Analysis

2 Company Profiles
    2.1 Grail, Inc.
        2.1.1 Grail, Inc. Details
        2.1.2 Grail, Inc. Major Business
        2.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.1.4 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Grail, Inc. Recent Developments and Future Plans
    2.2 Guardant Health, Inc.
        2.2.1 Guardant Health, Inc. Details
        2.2.2 Guardant Health, Inc. Major Business
        2.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.2.4 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Guardant Health, Inc. Recent Developments and Future Plans
    2.3 Biodesix, Inc.
        2.3.1 Biodesix, Inc. Details
        2.3.2 Biodesix, Inc. Major Business
        2.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.3.4 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Biodesix, Inc. Recent Developments and Future Plans
    2.4 Exosome Diagnostics
        2.4.1 Exosome Diagnostics Details
        2.4.2 Exosome Diagnostics Major Business
        2.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Solutions
        2.4.4 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Exosome Diagnostics Recent Developments and Future Plans
    2.5 Freenome Inc.
        2.5.1 Freenome Inc. Details
        2.5.2 Freenome Inc. Major Business
        2.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.5.4 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Freenome Inc. Recent Developments and Future Plans
    2.6 LungLife AI, Inc.
        2.6.1 LungLife AI, Inc. Details
        2.6.2 LungLife AI, Inc. Major Business
        2.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.6.4 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 LungLife AI, Inc. Recent Developments and Future Plans
    2.7 Inivata Ltd.
        2.7.1 Inivata Ltd. Details
        2.7.2 Inivata Ltd. Major Business
        2.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Solutions
        2.7.4 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Inivata Ltd. Recent Developments and Future Plans
    2.8 Personal Genome Diagnostics, Inc.
        2.8.1 Personal Genome Diagnostics, Inc. Details
        2.8.2 Personal Genome Diagnostics, Inc. Major Business
        2.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.8.4 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Personal Genome Diagnostics, Inc. Recent Developments and Future Plans
    2.9 CellMax Life
        2.9.1 CellMax Life Details
        2.9.2 CellMax Life Major Business
        2.9.3 CellMax Life Circulating Tumor DNA Diagnostics Product and Solutions
        2.9.4 CellMax Life Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 CellMax Life Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Circulating Tumor DNA Diagnostics Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Circulating Tumor DNA Diagnostics Players Market Share in 2021
        3.2.2 Top 10 Circulating Tumor DNA Diagnostics Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Circulating Tumor DNA Diagnostics Players Head Office, Products and Services Provided
    3.4 Circulating Tumor DNA Diagnostics Mergers & Acquisitions
    3.5 Circulating Tumor DNA Diagnostics New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Circulating Tumor DNA Diagnostics Revenue and Market Share by Type (2017-2022)
    4.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
    5.1 Global Circulating Tumor DNA Diagnostics Revenue Market Share by Application (2017-2022)
    5.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
    6.1 North America Circulating Tumor DNA Diagnostics Revenue by Type (2017-2028)
    6.2 North America Circulating Tumor DNA Diagnostics Revenue by Application (2017-2028)
    6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country
        6.3.1 North America Circulating Tumor DNA Diagnostics Revenue by Country (2017-2028)
        6.3.2 United States Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        6.3.3 Canada Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        6.3.4 Mexico Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
    7.1 Europe Circulating Tumor DNA Diagnostics Revenue by Type (2017-2028)
    7.2 Europe Circulating Tumor DNA Diagnostics Revenue by Application (2017-2028)
    7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country
        7.3.1 Europe Circulating Tumor DNA Diagnostics Revenue by Country (2017-2028)
        7.3.2 Germany Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        7.3.3 France Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        7.3.5 Russia Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        7.3.6 Italy Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Type (2017-2028)
    8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Application (2017-2028)
    8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region
        8.3.1 Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Region (2017-2028)
        8.3.2 China Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        8.3.3 Japan Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        8.3.4 South Korea Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        8.3.5 India Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        8.3.7 Australia Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
    9.1 South America Circulating Tumor DNA Diagnostics Revenue by Type (2017-2028)
    9.2 South America Circulating Tumor DNA Diagnostics Revenue by Application (2017-2028)
    9.3 South America Circulating Tumor DNA Diagnostics Market Size by Country
        9.3.1 South America Circulating Tumor DNA Diagnostics Revenue by Country (2017-2028)
        9.3.2 Brazil Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        9.3.3 Argentina Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Type (2017-2028)
    10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Application (2017-2028)
    10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country
        10.3.1 Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Country (2017-2028)
        10.3.2 Turkey Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)
        10.3.4 UAE Circulating Tumor DNA Diagnostics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Circulating Tumor DNA Diagnostics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Circulating Tumor DNA Diagnostics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Circulating Tumor DNA Diagnostics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Circulating Tumor DNA Diagnostics Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Region (2023-2028)
    Table 6. Grail, Inc. Corporate Information, Head Office, and Major Competitors
    Table 7. Grail, Inc. Major Business
    Table 8. Grail, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 9. Grail, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. Guardant Health, Inc. Corporate Information, Head Office, and Major Competitors
    Table 11. Guardant Health, Inc. Major Business
    Table 12. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 13. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. Biodesix, Inc. Corporate Information, Head Office, and Major Competitors
    Table 15. Biodesix, Inc. Major Business
    Table 16. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 17. Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Exosome Diagnostics Corporate Information, Head Office, and Major Competitors
    Table 19. Exosome Diagnostics Major Business
    Table 20. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Solutions
    Table 21. Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. Freenome Inc. Corporate Information, Head Office, and Major Competitors
    Table 23. Freenome Inc. Major Business
    Table 24. Freenome Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 25. Freenome Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. LungLife AI, Inc. Corporate Information, Head Office, and Major Competitors
    Table 27. LungLife AI, Inc. Major Business
    Table 28. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 29. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Inivata Ltd. Corporate Information, Head Office, and Major Competitors
    Table 31. Inivata Ltd. Major Business
    Table 32. Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 33. Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. Personal Genome Diagnostics, Inc. Corporate Information, Head Office, and Major Competitors
    Table 35. Personal Genome Diagnostics, Inc. Major Business
    Table 36. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 37. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. CellMax Life Corporate Information, Head Office, and Major Competitors
    Table 39. CellMax Life Major Business
    Table 40. CellMax Life Circulating Tumor DNA Diagnostics Product and Solutions
    Table 41. CellMax Life Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. Global Circulating Tumor DNA Diagnostics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 43. Global Circulating Tumor DNA Diagnostics Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 44. Breakdown of Circulating Tumor DNA Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 45. Circulating Tumor DNA Diagnostics Players Head Office, Products and Services Provided
    Table 46. Circulating Tumor DNA Diagnostics Mergers & Acquisitions in the Past Five Years
    Table 47. Circulating Tumor DNA Diagnostics New Entrants and Expansion Plans
    Table 48. Global Circulating Tumor DNA Diagnostics Revenue (USD Million) by Type (2017-2022)
    Table 49. Global Circulating Tumor DNA Diagnostics Revenue Share by Type (2017-2022)
    Table 50. Global Circulating Tumor DNA Diagnostics Revenue Forecast by Type (2023-2028)
    Table 51. Global Circulating Tumor DNA Diagnostics Revenue by Application (2017-2022)
    Table 52. Global Circulating Tumor DNA Diagnostics Revenue Forecast by Application (2023-2028)
    Table 53. North America Circulating Tumor DNA Diagnostics Revenue by Type (2017-2022) & (USD Million)
    Table 54. North America Circulating Tumor DNA Diagnostics Revenue by Type (2023-2028) & (USD Million)
    Table 55. North America Circulating Tumor DNA Diagnostics Revenue by Application (2017-2022) & (USD Million)
    Table 56. North America Circulating Tumor DNA Diagnostics Revenue by Application (2023-2028) & (USD Million)
    Table 57. North America Circulating Tumor DNA Diagnostics Revenue by Country (2017-2022) & (USD Million)
    Table 58. North America Circulating Tumor DNA Diagnostics Revenue by Country (2023-2028) & (USD Million)
    Table 59. Europe Circulating Tumor DNA Diagnostics Revenue by Type (2017-2022) & (USD Million)
    Table 60. Europe Circulating Tumor DNA Diagnostics Revenue by Type (2023-2028) & (USD Million)
    Table 61. Europe Circulating Tumor DNA Diagnostics Revenue by Application (2017-2022) & (USD Million)
    Table 62. Europe Circulating Tumor DNA Diagnostics Revenue by Application (2023-2028) & (USD Million)
    Table 63. Europe Circulating Tumor DNA Diagnostics Revenue by Country (2017-2022) & (USD Million)
    Table 64. Europe Circulating Tumor DNA Diagnostics Revenue by Country (2023-2028) & (USD Million)
    Table 65. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Type (2017-2022) & (USD Million)
    Table 66. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Type (2023-2028) & (USD Million)
    Table 67. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Application (2017-2022) & (USD Million)
    Table 68. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Application (2023-2028) & (USD Million)
    Table 69. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Region (2017-2022) & (USD Million)
    Table 70. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue by Region (2023-2028) & (USD Million)
    Table 71. South America Circulating Tumor DNA Diagnostics Revenue by Type (2017-2022) & (USD Million)
    Table 72. South America Circulating Tumor DNA Diagnostics Revenue by Type (2023-2028) & (USD Million)
    Table 73. South America Circulating Tumor DNA Diagnostics Revenue by Application (2017-2022) & (USD Million)
    Table 74. South America Circulating Tumor DNA Diagnostics Revenue by Application (2023-2028) & (USD Million)
    Table 75. South America Circulating Tumor DNA Diagnostics Revenue by Country (2017-2022) & (USD Million)
    Table 76. South America Circulating Tumor DNA Diagnostics Revenue by Country (2023-2028) & (USD Million)
    Table 77. Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Type (2017-2022) & (USD Million)
    Table 78. Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Type (2023-2028) & (USD Million)
    Table 79. Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Application (2017-2022) & (USD Million)
    Table 80. Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Application (2023-2028) & (USD Million)
    Table 81. Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Country (2017-2022) & (USD Million)
    Table 82. Middle East & Africa Circulating Tumor DNA Diagnostics Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Circulating Tumor DNA Diagnostics Picture
    Figure 2. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type in 2021
    Figure 3. Test Kits
    Figure 4. Reagents
    Figure 5. Circulating Tumor DNA Diagnostics Revenue Market Share by Application in 2021
    Figure 6. Hospitals Picture
    Figure 7. Diagnostics Laboratories Picture
    Figure 8. Research Laboratories Picture
    Figure 9. Academic Research Institutes Picture
    Figure 10. Global Circulating Tumor DNA Diagnostics Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 11. Global Circulating Tumor DNA Diagnostics Revenue and Forecast (2017-2028) & (USD Million)
    Figure 12. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Region (2017-2028)
    Figure 13. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Region in 2021
    Figure 14. North America Circulating Tumor DNA Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 15. Europe Circulating Tumor DNA Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 16. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 17. South America Circulating Tumor DNA Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 18. Middle East and Africa Circulating Tumor DNA Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 19. Circulating Tumor DNA Diagnostics Market Drivers
    Figure 20. Circulating Tumor DNA Diagnostics Market Restraints
    Figure 21. Circulating Tumor DNA Diagnostics Market Trends
    Figure 22. Grail, Inc. Recent Developments and Future Plans
    Figure 23. Guardant Health, Inc. Recent Developments and Future Plans
    Figure 24. Biodesix, Inc. Recent Developments and Future Plans
    Figure 25. Exosome Diagnostics Recent Developments and Future Plans
    Figure 26. Freenome Inc. Recent Developments and Future Plans
    Figure 27. LungLife AI, Inc. Recent Developments and Future Plans
    Figure 28. Inivata Ltd. Recent Developments and Future Plans
    Figure 29. Personal Genome Diagnostics, Inc. Recent Developments and Future Plans
    Figure 30. CellMax Life Recent Developments and Future Plans
    Figure 31. Global Circulating Tumor DNA Diagnostics Revenue Share by Players in 2021
    Figure 32. Circulating Tumor DNA Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 33. Global Top 3 Players Circulating Tumor DNA Diagnostics Revenue Market Share in 2021
    Figure 34. Global Top 10 Players Circulating Tumor DNA Diagnostics Revenue Market Share in 2021
    Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 36. Global Circulating Tumor DNA Diagnostics Revenue Share by Type in 2021
    Figure 37. Global Circulating Tumor DNA Diagnostics Market Share Forecast by Type (2023-2028)
    Figure 38. Global Circulating Tumor DNA Diagnostics Revenue Share by Application in 2021
    Figure 39. Global Circulating Tumor DNA Diagnostics Market Share Forecast by Application (2023-2028)
    Figure 40. North America Circulating Tumor DNA Diagnostics Sales Market Share by Type (2017-2028)
    Figure 41. North America Circulating Tumor DNA Diagnostics Sales Market Share by Application (2017-2028)
    Figure 42. North America Circulating Tumor DNA Diagnostics Revenue Market Share by Country (2017-2028)
    Figure 43. United States Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 44. Canada Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 45. Mexico Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 46. Europe Circulating Tumor DNA Diagnostics Sales Market Share by Type (2017-2028)
    Figure 47. Europe Circulating Tumor DNA Diagnostics Sales Market Share by Application (2017-2028)
    Figure 48. Europe Circulating Tumor DNA Diagnostics Revenue Market Share by Country (2017-2028)
    Figure 49. Germany Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 50. France Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 51. United Kingdom Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 52. Russia Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 53. Italy Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 54. Asia-Pacific Circulating Tumor DNA Diagnostics Sales Market Share by Type (2017-2028)
    Figure 55. Asia-Pacific Circulating Tumor DNA Diagnostics Sales Market Share by Application (2017-2028)
    Figure 56. Asia-Pacific Circulating Tumor DNA Diagnostics Revenue Market Share by Region (2017-2028)
    Figure 57. China Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 58. Japan Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 59. South Korea Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 60. India Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 61. Southeast Asia Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 62. Australia Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 63. South America Circulating Tumor DNA Diagnostics Sales Market Share by Type (2017-2028)
    Figure 64. South America Circulating Tumor DNA Diagnostics Sales Market Share by Application (2017-2028)
    Figure 65. South America Circulating Tumor DNA Diagnostics Revenue Market Share by Country (2017-2028)
    Figure 66. Brazil Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 67. Argentina Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 68. Middle East and Africa Circulating Tumor DNA Diagnostics Sales Market Share by Type (2017-2028)
    Figure 69. Middle East and Africa Circulating Tumor DNA Diagnostics Sales Market Share by Application (2017-2028)
    Figure 70. Middle East and Africa Circulating Tumor DNA Diagnostics Revenue Market Share by Country (2017-2028)
    Figure 71. Turkey Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 72. Saudi Arabia Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 73. UAE Circulating Tumor DNA Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. Methodology
    Figure 75. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life

Related Reports

Global Circulating Tumor DNA Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Circulating Tumor DNA Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 27 Feb 2023

date Medical Care

According to our (Global Info Research) latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Circulating Tumor DNA Diagnostics Supply, Demand and Key Producers, 2023-2029

Global Circulating Tumor DNA Diagnostics Supply, Demand and Key Producers, 2023-2029

date 23 Mar 2023

date Medical Care

The global Circulating Tumor DNA Diagnostics market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Circulating Tumor DNA Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Circulating Tumor DNA Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 26 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD 13180 million in 2023 and is forecast to a readjusted size of USD 18990 million by 2030 with a CAGR of 5.4% during review period.

Product Tags

circulating tumor dna diagnostics

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>